Translating new insights into treatment optimisation in multiple sclerosis.
Fazekas
Franz
F
Kieseier
Bernd C
BC
D000906:Antibodies / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018450:Disease Progression; D015195:Drug Design; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D014855:Wallerian Degeneration / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology
D000906:Antibodies; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate